Healthcare Access for Patients With Inflammatory Bowel Disease in the United States: A Survey by the Crohn's & Colitis Foundation

被引:1
|
作者
Jordan, Ariel A. [1 ]
Bhat, Shubha [2 ,3 ]
Ali, Tauseef [4 ]
Brunskill, Sarah R. [5 ]
Clusen, Nancy A. [5 ]
Maltz, Ross M. [6 ,7 ]
Moise, Ced [5 ]
Sun, Xiaofan [5 ]
Thomas, Harry J. [8 ]
Ray, Cassie [9 ]
Harkins-Schwarz, Mary [9 ]
Ehrlich, Orna G. [9 ]
机构
[1] Univ Michigan, Dept Internal Med, Ann Arbor, MI USA
[2] Cleveland Clin Fdn, Dept Pharm, Cleveland, OH USA
[3] Cleveland Clin Fdn, Dept Digest Dis Inst, Cleveland, OH USA
[4] SSM Hlth St Anthony Hosp Digest Care, Crohns & Colitis Ctr, Oklahoma City, OK USA
[5] Mathematica, Princeton, NJ USA
[6] Nationwide Childrens Hosp, Div Pediat Gastroenterol Hepatol & Nutr, Columbus, OH USA
[7] Ohio State Wexner Med Ctr, Dept Pediat, Columbus, OH USA
[8] Austin Gastroenterol, Austin, TX USA
[9] Crohns & Colitis Fdn, 733 Third Ave,Suite 510, New York, NY 10017 USA
关键词
inflammatory bowel disease; insurance; barriers to care; Crohn's disease; ulcerative colitis; BARRIERS;
D O I
10.1093/ibd/izae237
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background A prior survey disseminated in 2017 identified that healthcare access barriers exist and significantly affect patients with inflammatory bowel disease (IBD). We sought to identify, through an updated survey, the healthcare access barriers that patients continue to face, with a focus on socioeconomic factors and patient awareness of resources to navigate existing barriers.Methods A 52-question online survey evaluating (1) access to healthcare professionals, medications, and procedures; (2) associated financial challenges; and (3) patient awareness of education and advocacy tools to navigate IBD care barriers, was disseminated through multiple channels to IBD patients and their caregivers.Results Of the 2281 completed responses, patients on advanced specialty medications, younger than 65 years of age, or on employer insurance experienced significantly greater issues with insurance barriers to accessing medications and coverage of medically necessary tests/treatments. Patients who live in areas of concentrated poverty were more likely to experience poor health outcomes when subjected to step therapy compared to patients who did not. Additionally, patients were more likely to experience one or more financial barriers or trade-offs if the patient used an advanced specialty medicine or lived in an area with concentrated poverty.Conclusions While there have been significant and numerous advancements in IBD treatments, patients with IBD continue to experience barriers to healthcare access and treatment and financial struggles. Ongoing awareness and advocacy efforts focused on healthcare system reform and related policies to further minimize care disparities and barriers remain vital. Patients with inflammatory bowel disease in the United States experience financial struggles and barriers to healthcare access and treatment. Ongoing awareness and advocacy efforts focused on healthcare system reform and related policies to minimize care disparities and barriers remain vital. Graphical Abstract
引用
收藏
页数:14
相关论文
共 50 条
  • [31] Dietary Supplement Therapies for Inflammatory Bowel Disease: Crohn's Disease and Ulcerative Colitis
    Parian, Alyssa
    Limketkai, Berkeley N.
    CURRENT PHARMACEUTICAL DESIGN, 2016, 22 (02) : 180 - 188
  • [32] The role of HLA complex in inflammatory bowel disease: Crohn's disease and ulcerative colitis
    Lopez, Ruth
    Lucas, Daniel
    Campillo, Jose A.
    Salama, Hortensia
    Martinez, Pedro
    Valdes, Mariano
    Botella, Carmen
    Minguela, Alfredo
    Miras, Manuel
    Alvarez-Lopez, Maria R.
    Carballo, Fernando
    Muro, Manuel
    TISSUE ANTIGENS, 2009, 73 (05): : 474 - 474
  • [33] Optimizing biologic therapies for inflammatory bowel disease (ulcerative colitis and crohn’s disease)
    Marc Ferrante
    Geert D’Haens
    Paul Rutgeerts
    Séverine Vermeire
    Gert Van Assche
    Current Gastroenterology Reports, 2009, 11 (6) : 504 - 508
  • [34] Osteoporosis in inflammatory bowel disease - Results of a survey among members of the German Crohn's & Ulcerative Colitis Association
    von Tirpitz, C
    Steder-Neukamm, U
    Glas, K
    Sander, S
    Ring, C
    Klaus, J
    Reinshagen, M
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2003, 41 (12): : 1145 - 1150
  • [35] COST BURDEN OF CROHN'S DISEASE AND ULCERATIVE COLITIS IN THE UNITED STATES
    Chen, C.
    Xiao, H.
    VALUE IN HEALTH, 2016, 19 (07) : A881 - A881
  • [36] Assessment instruments for psychosocial stress in patients with chronic inflammatory bowel disease, Crohn's disease and ulcerative colitis
    Kunzendorf, S
    Benninghoven, D
    Straubinger, K
    Jantschek, G
    PSYCHOTHERAPIE PSYCHOSOMATIK MEDIZINISCHE PSYCHOLOGIE, 2004, 54 (02) : 100 - 100
  • [37] Fiber and the Risk of Flaring in Patients With Inflammatory Bowel Diseases: Lessons From the Crohn's and Colitis Foundation of America Database
    Kaplan, Gilaad G.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2016, 14 (08) : 1137 - 1139
  • [38] Patient knowledge in inflammatory bowel disease: the Crohn's and Colitis Knowledge Score
    Wardle, Richard A.
    Mayberry, John F.
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2014, 26 (01) : 1 - 5
  • [39] Interdisciplinary guidelines: Inflammatory bowel diseases (Crohn's disease, ulcerative colitis)
    Betzler, M
    EFFICIENCY AND ECONOMICS OF CLINICAL CARE AND RESEARCH IN SURGERY, 1997, SUPPL : 109 - 113
  • [40] Interdisciplinary guidelines: Inflammatory bowel diseases - Crohn's disease, ulcerative colitis
    Caspary, WF
    EFFICIENCY AND ECONOMICS OF CLINICAL CARE AND RESEARCH IN SURGERY, 1997, SUPPL : 100 - 108